6/17/2022 1:02:07 AM
Addex Ends Dipraglurant Phase 2b/3 Study For Dyskinesia Associated With Parkinson's Disease
5/27/2022 1:04:47 AM
Addex's Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study Fails To Meet Objectives
4/13/2022 1:04:25 AM
Addex Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study; Sees Top-line Data In Q2
3/10/2022 1:20:13 AM
Addex FY Loss Per Share CHF 0.45 Vs Loss CHF 0.48 Last Year
9/29/2021 1:06:48 AM
Addex Therapeutics Begins Phase 2a Clinical Study With Dipraglurant As A Potential Treatment For Blepharospasm
9/22/2021 1:50:22 AM
CMTA And Addex Therapeutics Enter Collaboration To Advance GABA B PAM As Potential Treatment For CMT1A
6/30/2021 1:30:48 AM
Addex Therapeutics Enters Sales Agreement With Cantor Fitzgerald To Offer ADSs Through At-the-market Offering Program
6/29/2021 1:04:02 AM
Addex Therapeutics Begins Pivotal Phase 2b/3 Study Of Dipraglurant For Dyskinesia Associated With Parkinson’s Disease
6/17/2021 1:16:38 AM
Addex Therapeutics Says Shareholders Approved All Proposals Of Board In Its 2021 AGM
6/7/2021 1:03:50 AM
Addex Enrolls First Patients In Phase 2 Clinical Study Of JNJ-40411813 In Patients With Epilepsy
2/24/2021 4:14:59 AM
Enamine Extend Collaboration With Addex Therapeutics
1/21/2021 1:03:42 AM
Addex Therapeutics Receives IND Approval For ADX71149 From FDA To Start Phase 2a Clinical Study In Epilepsy